Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083658 | PMC |
| http://dx.doi.org/10.1093/rheumatology/keab290 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
25 Years of Biologics For The Treatment of Pediatric Rheumatic Diseases - Advances in Prognosis and Ongoing Challenges.
Arthritis Care Res (Hoboken)
December 2024
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Article Synopsis
- Over 300,000 children in the U.S. have pediatric rheumatic diseases (PRDs), with juvenile idiopathic arthritis (JIA), childhood-onset systemic lupus erythematosus (cSLE), and juvenile dermatomyositis (JDM) being the most prevalent.
- The first biologic therapy for JIA, Etanercept, was approved in 1999, followed by other similar treatments that have significantly improved disease outcomes, though options for cSLE and JDM remain limited.
- The review explores the challenges in treating various PRDs, highlights advancements in treatment, and discusses current regulatory conditions affecting bDMARD and tsDMARD approvals.
Panniculitis in dermatomyositis: A systematic review of the clinicopathologic features.
JAAD Int
February 2025
Division of Dermatology, Department of Medicine, The University of the West Indies, Mona Campus, Kingston, Jamaica.
Background: Panniculitis in patients with dermatomyositis (PDMS) is rare.
Objectives: Assess the clinicopathologic features described for PDMS.
Methods: A systematic review of the PubMed/MEDLINE database was performed.
Characteristics of Patients with Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada.
J Cutan Med Surg
November 2024
Michael G. DeGroote School of Medicine, Hamilton, ON, Canada.
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by progressive muscle weakness and distinctive cutaneous findings. The exact incidence and prevalence of DM in the general population is largely unknown, and data on demographic and clinical features in patients in Canada are lacking. This study aimed to comprehensively evaluate the patients with DM in Southwestern Ontario, Canada.
View Article and Find Full Text PDFNailfold microscopy in adult-onset dermatomyositis in association with myositis antibodies.
Arch Dermatol Res
November 2024
Center for Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, NJ, USA.
Dermatomyositis (DM) is an immune mediated inflammatory disease classically associated with muscular and cutaneous involvement. Existing studies have suggested characteristic nailfold findings may be observed in DM, indicating a potential role for nailfold microscopic examination in the diagnosis of DM. To that end, we performed a systematic review of literature pertaining to nailfold microscopic, capillaroscopic, and dermoscopic findings observed in patients with DM, with a secondary review of the association of nailfold microscopic findings with myositis-specific antibody (MSA) and myositis-associated antibody (MAA) status.
View Article and Find Full Text PDFA retrospective study for clinical characteristics of 293 patients with dermatomyositis.
Medicine (Baltimore)
November 2024
Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
This retrospective study aimed to investigate differences in clinical characteristics between different antibody phenotypes in patients with dermatomyositis (DM). Two hundred and ninety-three patients with DM were included in this study from September 2018 to September 2023. We collected basic clinical data from the patients, using statistical methods to analyze the clinical characteristics, and used survival analysis and COX regression to assess the prognosis of the patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!